Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Matthieu Million, Jean‐Christophe Lagier, Philippe Gautret, et al.
Travel Medicine and Infectious Disease (2020) Vol. 35, pp. 101738-101738
Open Access | Times Cited: 479

Showing 26-50 of 479 citing articles:

Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology
Maicon Falavigna, Verônica Colpani, Cinara Stein, et al.
Revista Brasileira de Terapia Intensiva (2020) Vol. 32, Iss. 2
Open Access | Times Cited: 119
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
Laurence Albigès, Stéphanie Foulon, Arnaud Bayle, et al.
Nature Cancer (2020) Vol. 1, Iss. 10, pp. 965-975
Open Access | Times Cited: 115
Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial
Ehsan Sekhavati, Fatemeh Jafari, SeyedAhmad SeyedAlinaghi, et al.
International Journal of Antimicrobial Agents (2020) Vol. 56, Iss. 4, pp. 106143-106143
Open Access | Times Cited: 112
A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment
Ramy Mohamed Ghazy, Abdallah Almaghraby, Ramy Shaaban, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 107
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study
Roland Derwand, Martin Scholz, Vladimir Zelenko
International Journal of Antimicrobial Agents (2020) Vol. 56, Iss. 6, pp. 106214-106214
Open Access | Times Cited: 102
Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation
Mathieu Gendrot, Julien Andréani, Manon Boxberger, et al.
Travel Medicine and Infectious Disease (2020) Vol. 37, pp. 101873-101873
Open Access | Times Cited: 99
Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis
Harvey A. Risch
American Journal of Epidemiology (2020) Vol. 189, Iss. 11, pp. 1218-1226
Open Access | Times Cited: 96
Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose
Cassandra R. Doyno, Diana M Sobieraj, William L. Baker
Clinical Toxicology (2020) Vol. 59, Iss. 1, pp. 12-23
Open Access | Times Cited: 95
COVID-19, cytokines, inflammation, and spices: How are they related?
Ajaikumar B. Kunnumakkara, Varsha Rana, Parama Dey, et al.
Life Sciences (2021) Vol. 284, pp. 119201-119201
Open Access | Times Cited: 95
Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019
Pankaj Bansal, Amandeep Goyal, Austin Cusick, et al.
Annals of Medicine (2020) Vol. 53, Iss. 1, pp. 117-134
Open Access | Times Cited: 91
Clinical characteristics, laboratory findings, radiographic signs and outcomes of 61,742 patients with confirmed COVID-19 infection: A systematic review and meta-analysis
Ali Pormohammad, Saied Ghorbani, Behzad Baradaran, et al.
Microbial Pathogenesis (2020) Vol. 147, pp. 104390-104390
Open Access | Times Cited: 88
Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19
Moussa Sehailia, Smaïn Chemat
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 16, pp. 6184-6194
Open Access | Times Cited: 88
In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2
Mathieu Gendrot, Julien Andréani, Priscilla Jardot, et al.
Molecules (2020) Vol. 25, Iss. 21, pp. 5064-5064
Open Access | Times Cited: 87
Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19
Zi‐Ning Lei, Zhuo‐Xun Wu, Shaowei Dong, et al.
Pharmacology & Therapeutics (2020) Vol. 216, pp. 107672-107672
Open Access | Times Cited: 86
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
Omkar Indari, Shweta Jakhmola, E. Manivannan, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 86
An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19)
Saibal Das, Subhrojyoti Bhowmick, Sayali Tiwari, et al.
Clinical Drug Investigation (2020) Vol. 40, Iss. 7, pp. 591-601
Open Access | Times Cited: 85
RETRACTED ARTICLE: Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial
Sherief Abd‐Elsalam, Shaimaa Soliman, Eslam Saber Esmail, et al.
Biological Trace Element Research (2020) Vol. 199, Iss. 10, pp. 3642-3646
Open Access | Times Cited: 84
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)
Peter A. McCullough, Paul Alexander, Robin Armstrong, et al.
Reviews in Cardiovascular Medicine (2020) Vol. 21, Iss. 4
Open Access | Times Cited: 80
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19
Andrea Cortegiani, Mariachiara Ippolito, Giulia Ingoglia, et al.
Journal of Critical Care (2020) Vol. 59, pp. 176-190
Open Access | Times Cited: 79
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs
Alessandra Bartoli, Filippo Gabrielli, Tatiana Alicandro, et al.
Internal and Emergency Medicine (2021) Vol. 16, Iss. 2, pp. 281-308
Open Access | Times Cited: 78
The “Infodemic” of COVID‐19
Daniel H. Solomon, Richard Bucala, Mariana J. Kaplan, et al.
Arthritis & Rheumatology (2020) Vol. 72, Iss. 11, pp. 1806-1808
Open Access | Times Cited: 75
Investigating the Spread of Coronavirus Disease via Edge-AI and Air Pollution Correlation
V. Gomathy, K. Janarthanan, Fadi Al‐Turjman, et al.
ACM Transactions on Internet Technology (2021) Vol. 21, Iss. 4, pp. 1-10
Closed Access | Times Cited: 73
Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world
Matthieu Million, Philippe Gautret, Philippe Colson, et al.
New Microbes and New Infections (2020) Vol. 38, pp. 100709-100709
Open Access | Times Cited: 71
Navigating the Uncertainties of COVID-19–Associated Aspergillosis: A Comparison With Influenza-Associated Aspergillosis
Frédéric Lamoth, Russell E. Lewis, Thomas J. Walsh, et al.
The Journal of Infectious Diseases (2021)
Open Access | Times Cited: 60
Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19
Vincent J. Venditto, Dalia Haydar, Ahmed Abdel‐Latif, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 56

Scroll to top